Detalhe da pesquisa
1.
Oncological and urinary outcomes following low-dose-rate brachytherapy with a median follow-up of 11.8 years.
BJU Int
; 130 Suppl 3: 40-45, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35791775
2.
Corrigendum: Correction of the Abstract. Focal therapy for prostate cancer with irreversible electroporation: Oncological and functional results of a single institution study.
Investig Clin Urol
; 63(4): 482, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35796143
3.
Focal therapy for prostate cancer with irreversible electroporation: Oncological and functional results of a single institution study.
Investig Clin Urol
; 63(3): 285-293, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35534217
4.
Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?
Investig Clin Urol
; 62(6): 650-657, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34729965
5.
Histological findings of totally embedded robot assisted laparoscopic radical prostatectomy (RALP) specimens in 1197 men with a negative (low risk) preoperative multiparametric magnetic resonance imaging (mpMRI) prostate lobe and clinical implications.
Prostate Cancer Prostatic Dis
; 24(2): 398-405, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32999464